

# A Modified Rheumatoid Arthritis Disease Activity Score Without Acute-phase Reactants (mDAS28) for Epidemiological Research

MARY J. BENTLEY, JEFFREY D. GREENBERG, and GEORGE W. REED

**ABSTRACT.** *Objective.* To develop and validate a modified version of the Disease Activity Score with 28 joint count (mDAS28), for use in epidemiological research, when acute-phase reactant values are unavailable.

*Methods.* In a cross-sectional development cohort (5729 patients), statistically significant predictors of the logarithm of erythrocyte sedimentation rate (lnESR) were identified. After computation of the mDAS28, a cross-sectional validation cohort (5578 patients) was used to evaluate internal, criterion, and construct validities. The ability of the mDAS28 to discriminate between disease states was also assessed. A second validation cohort (longitudinal, 336 pairs of patient visits) was used to assess sensitivity to change.

*Results.* Significant predictors of lnESR included tender and swollen joints with 28 counts, patient's and physician's assessments of global health, and patient's assessment of pain (visual analog scale 0–100 mm) and a physical function (modified Health Assessment Questionnaire 0–3; mHAQ). Satisfactory internal validity ( $\alpha = 0.72$ ) and strong criterion validity compared to the DAS28, the Simplified Disease Activity Index (SDAI), and the Clinical Disease Activity Index (CDAI) ( $r = 0.87$ – $0.96$ ) were found. Predictive validity was demonstrated by good correlation with the mHAQ ( $r = 0.58$ ). The mDAS28 showed substantial agreement with the DAS28, SDAI, and CDAI in discriminating between disease states ( $\kappa = 0.70$ – $0.77$ ) and moderate to substantial agreement between response levels ( $\kappa = 0.52$ – $0.73$ ). Both mDAS28 and DAS28 measures classified patients similarly in remission compared to the SDAI and CDAI. The mDAS28 was superior in detecting change (standardized response mean =  $0.58$ ) followed by the DAS28, CDAI, and SDAI.

*Conclusion.* The mDAS28 is a valid and sensitive tool to assess disease activity in epidemiological research, as an alternative to the DAS28, when acute-phase reactant values are unavailable. (J Rheumatol First Release July 1 2010; doi:10.3899/jrheum.090831)

## Key Indexing Terms:

DISEASE ACTIVITY SCORE                      DISEASE ACTIVITY SCORE 28 JOINT COUNT  
AMERICAN COLLEGE OF RHEUMATOLOGY                      DISEASE ACTIVITY MEASURES  
EUROPEAN LEAGUE AGAINST RHEUMATISM                      CLINICAL DISEASE ACTIVITY INDEX  
SIMPLIFIED DISEASE ACTIVITY INDEX

The Disease Activity Score with 28 joint count (DAS28)<sup>1</sup> is one of the most widely used and validated composite meas-

*From the Biostatistics Research Group, Department of Medicine, Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; and Department of Rheumatology, New York University Hospital for Joint Diseases, New York, New York, USA.*

*M.J. Bentley, PhD, MPH, Biostatistics Research Group, Department of Medicine, Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School; J.D. Greenberg, MD, MPH, Assistant Professor, Department of Rheumatology, New York University Hospital for Joint Diseases; G.W. Reed, PhD, Associate Professor, Biostatistics Research Group, Department of Medicine, Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School.*

*Address correspondence to M.J. Bentley, Department of Medicine, Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School, Shaw Building, SH2-222, 419 Belmont Street, Worcester, MA 01655, USA.*

*E-mail: maryjane.bentley@umassmed.edu*

*Accepted for publication May 20, 2010.*

ures of disease activity in rheumatology. It is a modified version of the original Disease Activity Score (DAS) developed by van der Heijde, *et al*<sup>2,3</sup> in 1990. It is regarded by many as the “gold standard” measure in rheumatoid arthritis (RA) and is required by several regulatory bodies when determining patient eligibility for biologic treatments. Among other disease activity instruments, the DAS28, as part of the European League Against Rheumatism (EULAR) response criteria<sup>4</sup>, has been a reliable measure of treatment efficacy in clinical trials, along with the American College of Rheumatology (ACR) improvement criteria<sup>5</sup>, and its use has been recommended by EULAR in the clinical management of RA<sup>6</sup>. In addition, DAS28 has been used as a benchmark for validation of several new composite indices<sup>7,8,9,10</sup>.

The DAS28 uses a mathematical formula to combine values of 4 of the 7 ACR/EULAR core set measures of disease activity, tender joint count (TJC) based on 28 counts,

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2010. All rights reserved.

swollen joint count (SJC) based on 28 counts, patient global health, and an acute-phase reactant, the erythrocyte sedimentation rate (ESR), to produce a continuous score. Several other composite measures have been developed: the Simplified Disease Activity Index (SDAI)<sup>11</sup> and the Clinical Disease Activity Index (CDAI)<sup>12</sup>. Both are computed by a simple summation of a subset of the core measures: TJC, SJC, patient global assessment of disease activity [PGA; visual analog scale (VAS) 0–10 cm], physician global assessment of disease activity (EGA; VAS 0–10 cm), and an acute-phase reactant, C-reactive protein (CRP). The SDAI contains CRP, but the CDAI does not. The ACR-N<sup>13</sup>, the hybrid measure of ACR improvement criteria, assesses the change in disease activity rather than the current disease activity. Composite measures that include only patient-reported outcomes, such as the patient activity score<sup>14</sup> and the RAPID3<sup>15</sup>, have been found to discriminate response in clinical trials.

However, all disease activity measures have some limitations. In settings where laboratory values such as ESR may be unavailable, such as in health services or epidemiological research, the utility of the DAS28 has been limited<sup>16</sup>. In clinical trials, ESR values are available as mandated by study protocol, allowing computation of the DAS28. But in some practice settings the ESR laboratory test is not ordered routinely, impeding calculation of the DAS28, and in epidemiological research, this causes the omission of patients with missing ESR values from further analysis<sup>16</sup>. It has been suggested that acute-phase reactants add little to composite disease activity measures<sup>12</sup>. In addition, ESR has been found to be normal in up to 40% of RA patients with active disease, suggesting that its value as a measure of disease activity may be limited<sup>16</sup>. Limitations in the DAS28, SDAI, and CDAI suggested in previous research<sup>7</sup> include the lack of a patient functional status measure such as the Health Assessment Questionnaire (HAQ), the best predictor of severe outcomes in RA<sup>17,18</sup>. The ACR-N or ACR improvement criteria measure change of disease activity over time and do not allow assessment of disease activity at one clinical visit.

Based on these limitations and to facilitate calculation of the DAS28 in epidemiological research, the aim of our study was to modify the DAS28 by replacing the acute-phase reactant, resulting in a modified DAS28 (mDAS28), and to assess its comparability with the DAS28 and its validity according to the Outcomes Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) recommendations<sup>19,20</sup>.

## MATERIALS AND METHODS

Subjects were selected from a large North American registry, the Consortium of Rheumatology Researchers of North America (CORRONA)<sup>21</sup>. The methods of this registry have been described<sup>22</sup>. Patients eligible for the study had all measures needed to calculate the DAS28. Patients who did not have all these components were excluded from further analysis. Demographic and disease activity measures of excluded and

included patients were compared in a separate analysis to determine whether any bias was entered due to sample selection.

The study utilized 3 samples, cross-sectional “development” and “validation” datasets and a longitudinal “validation” dataset (Table 1).

The first 2 datasets were from a cohort of 11,307 patients with RA. A cross-section of this cohort was obtained with information from the patient’s most recent visit. This cross-sectional cohort was randomly and evenly divided into “development” and “validation” datasets. The cross-sectional development dataset (n = 5729) was used to build a prediction model to identify statistically significant predictors of the logarithm of ESR (lnESR), and the cross-sectional validation dataset (n = 5578) was used to subsequently validate the mDAS28.

The third dataset, a longitudinal “validation” dataset, was from a cohort of 703 patients with RA who had 2 paired visits. The first visit involved initiation of a disease modifying antirheumatic drug (DMARD); the second visit occurred at least 3 months after the first. This longitudinal cohort was then divided randomly and evenly into “development” (n = 336 pairs) and “validation” datasets (n = 367 pairs). The longitudinal validation dataset was used to evaluate the mDAS28 as a measure of response.

Disease activity measures needed to compute the DAS28 were collected by a rheumatologist. Measures included the modified HAQ (mHAQ) score<sup>23</sup>, a measure of functional status, the patient visual analog pain score (PAIN), physician global assessment of disease activity (EGA), and duration of morning stiffness. DAS28 values were calculated according to its formula<sup>1</sup>:

$$\text{DAS28} = 0.56 \times \sqrt{(28\text{TJC})} + 0.28 \times \sqrt{(28\text{SJC})} + (0.70 \times \ln\text{ESR}) + 0.014 \times \text{PGA}$$

SDAI and CDAI values were also calculated according to their respective formulas<sup>11,12</sup> and used as comparators along with the DAS28 to validate the mDAS28. The EULAR response criteria were used to validate the mDAS28 as a measure of response. Response criteria for the SDAI and the CDAI, based on published absolute cutpoints<sup>24</sup> and change cutpoints<sup>25</sup>, were also calculated and used as additional comparators.

*Statistical analysis.* To develop the mDAS28, statistically significant predictors of the lnESR were identified in the cross-sectional development cohort, using univariate linear regression analysis. Candidate predictors of lnESR included TJC, SJC, PAIN, EGA, PGA, mHAQ, and duration of morning stiffness. Candidate variables significant at an alpha level of 0.10 were included in a multivariate model. Forward and backward stepwise regression was used to identify the most significant independent variables using a p value of 0.10 as the removal criterion. Multicollinearity between the significant independent variables, specified in the multivariable model, was determined using the variance inflation factor (VIF)<sup>26</sup>. Variables found to be collinear (VIF > 10) were dropped from the model. Goodness of fit of the model in predicting the dependent variable, lnESR, was assessed by R<sup>2</sup> statistic, a measure of the proportion of the variation explained by the regression<sup>27</sup>. The reliability and validity of the mDAS28 as a measure of disease activity and response was then evaluated in the cross-sectional and longitudinal validation datasets. Internal validity, the extent that items in a score measure the same outcome, was assessed using Cronbach’s alpha<sup>28</sup>. Criterion validity, the extent that a measure correlates with a “gold standard,” was examined by correlating mDAS28 scores with DAS28, SDAI, and CDAI. Both the simplified composite indices SDAI and CDAI were used as comparators to better assess criterion validity, since one contains an acute-phase reactant (SDAI) and the other does not. Predictive validity, the ability of a measure to predict future outcome of the disease, was examined by correlating the mDAS28 scores with the mHAQ. Both validities were assessed by Spearman rank correlation coefficients<sup>29</sup>. The amount of agreement between mDAS28 and the other disease activity indices to discriminate between different disease states of individual patients (remission, low, moderate, high) and between good, moderate, or none levels of response based on the EULAR response criteria was examined using weighted kappa statistics<sup>30</sup>. EULAR response criteria were calculated according to its algo-

Table 1. Demographic and clinical characteristics in cross-sectional and longitudinal cohorts. Values are mean (SD) unless otherwise indicated.

Characteristic	Cross-Sectional		Longitudinal <sup>†</sup>
	Development	Validation	Validation
Patients, no.	5729	5578	367
Age, yrs	60.1 (13.7)	60.3 (13.8)	58.7 (12.5)
Female, %	75.8	75.3	77.9
Caucasian, %	82.7	82.5	85.3
Rheumatoid factor positive, %	67.8	70	82
Disease duration, yrs	11.3 (10.1)	11.1 (9.9)	11.8 (10.0)
Disease activity characteristics			
Tender joints 0–28	3.37 (5.54)	3.38 (5.4)	5.65 (6.10)
Swollen joints 0–28	3.89 (5.54)	3.86 (5.53)	5.98 (5.50)
ESR, mm (normal < 20)	24.6 (22.3)	24.6 (22.1)	25.9 (22.6)
CRP, mg/dl (normal < 1.0)	2.96 (8.5)	2.96 (8.7)	2.8 (7.8)
Pain VAS assessment, 0–100	32.2 (26.6)	31.6 (25.9)	39.4 (26.7)
mHAQ, 0–3	0.40 (0.49)	0.39 (0.48)	0.50 (0.52)
Patient global assessment, 0–100	29.9 (25.9)	29.8 (25.9)	37.9 (26.84)
Physician global assessment, 0–100	19.5 (19.0)	19.4 (19.2)	29.4 (20.3)
Duration of stiffness, h	1.03 (2.4)	0.94 (2.11)	1.34 (3.11)
Disease activity composite measures			
mDAS28	3.41 (1.38)	3.40 (1.37)	4.21 (1.41)
DAS28	3.42 (1.54)	3.41 (1.54)	4.19 (1.59)
SDAI	15.0 (16.1)	14.9 (16.0)	20.5 (17.0)
CDAI	12.2 (12.0)	12.1 (12.0)	18.4 (13.0)

<sup>†</sup> Initiators of disease-modifying antirheumatic drugs. ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; VAS: visual analog scale; mHAQ: modified Health Assessment Questionnaire score; mDAS28: modified Disease Activity Score with 28 joint count; DAS28: Disease Activity Score with 28 joint count; SDAI: Simplified Disease Activity Index; CDAI: Clinical Disease Activity Index.

rithm (Figure 1). Since new cutpoints were not derived for the mDAS28, modified EULAR (mEULAR) response criteria were calculated according to the EULAR response criteria, using mDAS28 scores and DAS28 cutpoints.

SDAI and CDAI response criteria were derived in the same manner as the EULAR response criteria, with the exception that the absolute cutpoints as defined<sup>24</sup> and the change cutpoints as defined<sup>25</sup> for both measures were used instead of DAS28 cutpoints.

The sensitivity to change or responsiveness of the mDAS28, the ability of a measure to detect important changes over time after a treatment has been initiated, was evaluated by calculating the effect size (ES)<sup>30</sup> and standardized response mean (SRM)<sup>31</sup>. ES was calculated by taking the mean differences of the disease activity scores between the baseline and second

study visits (mean change scores) and dividing by the standard deviation of the baseline scores. SRM was calculated by taking the mean change scores and dividing the result by the standard deviation of the change scores. The values of the ES were small with a range of 0.2–0.5, moderate if 0.5–0.8, or large if > 0.8<sup>30</sup>. SRM were interpreted similarly<sup>31</sup>. Statistical analysis was carried out using Stata version 10.0 (Stata Corp., College Station, TX, USA)<sup>32</sup>.

## RESULTS

A total of 11,307 patients were eligible for the cross-sectional cohort, and 703 pairs of patients with initiation of a DMARD and at least 3 months until the first followup visit




Figure 1. Algorithm to calculate the EULAR Response Criteria using published absolute and change cutpoints. \*DAS28 absolute cutpoints. <sup>†</sup>DAS28 change cutpoints.

were eligible for the longitudinal cohort. Demographics and clinical characteristics for the cross-sectional development and validation dataset were generally similar (Table 1). Both cross-sectional datasets exhibited mild to moderate disease levels but, in the longitudinal validation dataset, disease activity measures had higher values. This would be expected since the patients in the longitudinal dataset were initiators of DMARD. A sensitivity analysis was performed between patients utilized in the study and the subset of patients who did not have sufficient disease data to calculate the DAS28, and their demographic and clinical characteristics were found to be comparable (data not shown).

*The modified DAS28 (mDAS28).* In the unadjusted univariate analysis, all 7 candidate predictors (TJC, SJC, PGA, EGA, PAIN, mHAQ, and morning stiffness) were found to significantly predict lnESR. Forward and backward stepwise regression analysis resulted in the same multivariable model with the following significant predictors: TJC, SJC, mHAQ, EGA, and PAIN (Table 2).

The PGA and duration of morning stiffness were significant in the unadjusted model but became insignificant when entered into the multivariable model. Upon examination of the functional associations between lnESR and several of the candidate predictors, transformations of TJC and SJC were performed to better fit the assumption of linearity. The multivariable model was refit after transforming the TJC and SJC to their logarithmic forms. A separate model was fit using TJC and SJC in the forms of log of (TJC + 1) and (SJC + 1) due to values of 0. No differences in the amount of variance were explained by these models when compared to the original model. In another series of models, TJC and SJC were both transformed to their square roots and refit in the multivariable model. Again, no difference was found with the amount of variance explained by this model compared to the original model. It was decided to use the model containing the square roots of TJC and SJC since the transformed forms could be combined with the squared forms of TJC and SJC that were already present in the DAS28 formula. Every possible interaction between the variables was also explored, but no significant interactions were found. The final model consisted of the 5 significant predictors of

lnESR: TJC, SJC, mHAQ, PAIN, and EGA. The regression equation for the lnESR was as follows:

$$\ln\text{ESR} = 2.42 - (0.037 \times \sqrt{28\text{TJC}}) + (0.041 \times \sqrt{28\text{SJC}}) + (0.35 \times \text{mHAQ}) + (0.001 \times \text{PAIN}) + (0.077 \times \text{EGA})$$

The model had  $R^2 = 0.08$ , indicating only 8% of the variation was explained by the model. The possibility of multicollinearity between the significant predictors was investigated using the VIF, and no collinearity was indicated; all VIF values were  $< 2.0$  (range 1.40–1.94).

Imputation of the fitted regression equation of the lnESR into the DAS28 formula in place of the observed lnESR resulted in the following modified version of the DAS28:

$$\text{mDAS28} = 0.56 \times \sqrt{(28\text{TJC})} + 0.28 \times \sqrt{(28\text{SJC})} + 0.70 [2.42 - (0.037 \times \sqrt{28\text{TJC}}) + (0.041 \times \sqrt{28\text{SJC}}) + (0.35 \times \text{mHAQ}) + (0.001 \times \text{PAIN}) + (0.077 \times \text{EGA})] + 0.014 \times \text{PGA}$$

The formula was simplified to its final form by combining the squared TJC and SJC terms:

$$\text{mDAS28} = 0.53 \times \sqrt{(28\text{TJC})} + 0.31 \times \sqrt{(28\text{SJC})} + 0.25 \times \text{mHAQ} + 0.001 \times \text{PAIN} + 0.005 \times \text{EGA} + 0.014 \times \text{PGA} + 1.694$$

### Validation of the mDAS28

*Measure of disease activity. Distributional properties.* The distributions of mDAS28 scores and the DAS28 scores differed, the DAS28 being normally distributed and the mDAS28 exhibiting right-skewness (Figure 2). SDAI and CDAI values were also right-skewed, as reported in other studies<sup>33,34</sup>.

The means (SD) of the DAS28 and mDAS28 were 3.42 (1.54) and 3.41 (1.38), respectively, in the cross-sectional development dataset and were similar in the 2 validation datasets (Table 1). Upon examination, it was found that both the mDAS28 and the DAS28 were almost identical in detecting remission and low disease activity. Using the DAS28, 894 (16%) patients had scores  $\leq 3.2$  and  $> 2.6$  (low disease) and 1871 (34%) had scores  $\leq 2.6$  (remission). When

Table 2. Results of forward and backwards stepwise linear regressions.

Predictors	Coefficient, $\beta$	Standard Error	p > t	(95% CI)
Disability Index (mHAQ)	0.345	0.033	< 0.001	(0.280 to 0.411)
Physician global assessment	0.077	0.001	< 0.001	(0.006 to 0.009)
Swollen joint score	0.041	0.011	< 0.001	(0.019 to 0.062)
Patient VAS for pain	0.001	0.001	0.033	(0.000 to 0.003)
Tender joint score	-0.037	0.013	0.004	(-0.064 to -0.012)
Constant	2.423	0.022	< 0.001	(2.378 to 2.467)

mHAQ: modified Health Assessment Questionnaire; VAS: visual analog scale.




Figure 2. Distribution properties of composite disease activity indices in the cross-sectional validation cohort (n = 5578).

the mDAS28 was used, 915 (17%) patients had scores  $\leq 3.2$  and  $> 2.6$  and 1939 (35%) had scores  $\leq 2.6$  (Table 3).

When the CDAI was used to classify patients, a larger proportion of patients was classified into low disease and fewer into remission compared to the DAS28 and mDAS28. The proportion of patients classified into remission and low disease activity by the SDAI was similar to that of the CDAI (Table 3).

**Internal consistency.** The mDAS28 had satisfactory internal

consistency ( $\alpha = 0.71$ ), while the DAS28, SDAI, and CDAI were not as valid internally ( $\alpha = 0.39, 0.61, 0.60$ , respectively).

**Criterion validity.** On a group level, the mDAS28 was strongly correlated with the DAS28, SDAI, and CDAI ( $r = 0.87, 0.91, 0.96$ , respectively). All correlations were significant ( $p < 0.001$ ).

**Predictive validity.** The mDAS28 was significantly correlated with the mHAQ ( $r = 0.58, p < 0.001$ ). DAS28, CDAI, and

Table 3. Proportion of patients classified in disease levels using composite indices in the cross-sectional validation cohort (n = 5578). Values are number (%).

Measure	Remission	Low	Moderate	High
mDAS28	1939 (35)	915 (17)	1936 (35)	732 (13)
DAS28	1871 (34)	894 (16)	1970 (35)	843 (15)
CDAI	1309 (23)	1874 (34)	1387 (25)	1008 (18)
SDAI <sup>†</sup>	618 (20)	1050 (34)	852 (28)	537 (18)

<sup>†</sup> For the SDAI, n = 3057 had SDAI scores. mDAS28: modified Disease Activity Score with 28 joint count; DAS28: Disease Activity Score with 28 joint count; CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity Index.

SDAI were also significantly correlated with the mHAQ but not as strongly ( $r = 0.51, 0.51, 0.51$ , respectively,  $p < 0.001$ ). Stronger correlation between mDAS28 and mHAQ would be expected given that the mHAQ is a component of the mDAS28.

*Ability to discriminate.* To determine the ability of the mDAS28 to classify individual patients by disease level, weighted kappa coefficients were used, and indicated strong agreement between mDAS28 and DAS28 ( $\kappa = 0.70$ ). Kappa values  $> 0.60$  indicate a substantial relationship<sup>35</sup>. There was strong agreement between mDAS28 and CDAI ( $\kappa = 0.77$ ) and between mDAS28 and SDAI ( $\kappa = 0.71$ ). Similar results were found between DAS28 and CDAI and DAS28 and SDAI ( $\kappa = 0.62, 0.63$ , respectively).

*Measure of response to treatment. Ability to discriminate.* Substantial agreement between the EULAR and the mEULAR was found in classifying individual patients ( $\kappa = 0.74$ ). However, only moderate agreement was found when mEULAR was compared to CDAI response criteria ( $\kappa = 0.52$ ) and SDAI response criteria ( $\kappa = 0.52$ ). Moderate agreements were also found when the EULAR response criteria were compared with the CDAI ( $\kappa = 0.46$ ) and SDAI response criteria ( $\kappa = 0.47$ ).

*Sensitivity to change.* Mean changes in scores of the mDAS28 and DAS28 from the baseline initiation visit to the followup visit were similar (Table 4). The mDAS28 was the most sensitive measure to detect change over time compared to DAS28, CDAI, and SDAI. mDAS28 had moderate ES (0.50) and SRM values (0.58) while DAS28 and CDAI both had moderate SRM values (0.57, 0.52) but small ES values (0.47, 0.45). The SDAI was the weakest measure to detect change, with ES of 0.37 and SRM of 0.45.

## DISCUSSION

Our study demonstrates that a modified version of the DAS28 calculated without the ESR, the mDAS28, performs as well as the DAS28 as a measure of both disease activity and response, and could be used as an alternative to the DAS28 in epidemiological research when ESR values are unavailable.

Measures such as DAS28 have been used successfully in

clinical trials where the goal was to measure the efficacy of therapies by comparing groups of patients. In our study, the mDAS28 was strongly correlated with DAS28, and also with the SDAI and CDAI on a group level. In addition, compared to the other disease activity indices, mDAS28 had the strongest association with the mHAQ ( $r = 0.58$ ). This would be expected given that the mHAQ is a component of the mDAS28. Makinen, *et al*<sup>7</sup> noted when developing the Mean Overall Index for Rheumatoid Arthritis (MOI-RA) that one of the limitations of the DAS28 was that it did not contain the HAQ<sup>36</sup>, considered the best predictor of outcomes in RA<sup>18,37,38</sup>. In studies comparing the HAQ with the mHAQ, both measures were found to be strongly correlated<sup>39</sup> and sensitive to change of treatment<sup>40,41,42</sup>. Since a measure should have face validity, the addition of the mHAQ as part of the mDAS28 strengthens the overall credibility of the measure.

The mean baseline values of the mDAS28 were almost identical to the mean baseline values of the DAS28 in all 3 cohorts — for cross-sectional development 3.41 (1.38) versus 3.42 (1.57), respectively; for cross-sectional validation 3.40 (1.37) versus 3.41 (1.54); and for longitudinal validation 4.21 (1.41) versus 4.19 (1.59). Classifying proportions of individual patients into the disease states of remission, low, moderate, and high disease activity, the mDAS28 again performed almost identically to the DAS28. The DAS28 classified 16% and 35% of patients into remission and low disease activity, respectively, whereas mDAS28 classified 16% and 34% into remission and low disease activity.

Since measurement tools need to assess individual patients, we examined the agreement of the measures when classifying individual patients according to disease levels, and the mDAS28 agreed strongly with the CDAI, SDAI, and DAS28 ( $\kappa = 0.70$ – $0.77$ ), despite the absence of the ESR as a component. The mDAS28 was also compared to the DAS28 for classifying patients according to their level of response using the EULAR response criteria. Strong agreement was found between the mEULAR and EULAR criteria ( $\kappa = 0.74$ ). However, only moderate agreement was found when the mEULAR criteria were compared with the CDAI and SDAI response criteria. The EULAR criteria were also moderately in agreement with the CDAI and SDAI response criteria.

Table 4. Sensitivity to change assessed by effect size (ES) and standardized response mean (SRM). Values are mean (SD) unless otherwise indicated.

Measure	Baseline, mean (SD)	Followup, mean (SD)	Change, mean (SD)	ES	SRM
mDAS28	4.21 (1.41)	3.50 (1.31)	0.698 (1.20)	0.50	0.58
DAS28	4.22 (1.55)	3.48 (1.48)	0.732 (1.28)	0.47	0.57
CDAI	18.37 (13.05)	12.49 (11.19)	5.88 (11.28)	0.45	0.52
SDAI	20.54 (17.04)	14.23 (11.75)	6.33 (14.17)	0.37	0.45

mDAS28: modified Disease Activity Score with 28 joint count; DAS28: Disease Activity Score with 28 joint count; CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity Index.

The mean changes in scores of the mDAS28 and DAS28 from baseline initiation to the followup visit were similar [ $\Delta = 0.698$  (1.20) vs  $\Delta = 0.732$  (1.28), respectively]. In addition, the mDAS28 demonstrated similar sensitivity to detect disease activity changes after initiation of a DMARD compared to the DAS28. These results suggest that the mDAS28 is a valid measure of disease activity and could be used to measure disease activity when DAS28 cannot be calculated.

Our effort to replace the logarithm of ESR by identifying significant predictors provides insight into the complexity of disease activity measurement. Although the mDAS28 performs similarly to the DAS28, the complexity of its formula limits its use, especially in a clinical setting, compared to simplified composite measures — the CDAI, SDAI, and MOI-RA. Thus, it may be more suitable for epidemiological research using data from registries rather than in daily routine patient monitoring. This would prevent the exclusion of patients with missing ESR values from epidemiological research studies.

A limitation of our study is the use of only one observational dataset to develop and validate the measure. Additional validations of the mDAS28 should be performed in other populations, such as a clinic trial dataset. Another potential criticism of the study could be that the patients had low to moderate disease activity. Again, additional investigations of the mDAS28 using populations with greater ranges of disease levels including high disease activity should be undertaken.

Our intent to modify the DAS28 by substituting other measures for the ESR was not to diminish the importance of the ESR as a measure of RA disease activity. In effect, we suggest physicians continue to order laboratory measures regularly in the clinic, as the ESR is an important measure of disease activity and longterm outcomes<sup>43</sup>. Modification of the DAS28 was done to allow a measure comparable to it to be devised for research settings where laboratory values such as the ESR are not available and the DAS28 cannot be calculated.

In this observational study, we developed a modified version of the DAS28 without the ESR value, and then demonstrated that the mDAS28 is comparable to the DAS28 for measuring RA disease activity and response. The mDAS28 was also found to be a valid outcome measure as it fulfilled most of the criteria recommended by the OMERACT initiative. The mDAS28 can be calculated when ESR values are unavailable, preventing patients being excluded in epidemiological research using disease registries. Further testing of the mDAS28 in other patient populations is recommended.

## REFERENCES

1. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:44-8.
2. van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score. *Ann Rheum Dis* 1990;49:916-20.
3. van der Heijde DM, van 't Hof MA, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. *J Rheumatol* 1993;20:579-81.
4. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. *Arthritis Rheum* 1996;39:34-40.
5. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;38:727-35.
6. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum* 2008;59:762-84.
7. Makinen H, Kautiainen H, Hannonen P, Sokka T. A new disease activity index for rheumatoid arthritis: Mean overall index for rheumatoid arthritis (MOI-RA). *J Rheumatol* 2008;35:1522-7.
8. Aletaha D, Stamm T, Smolen JS. Validation of the Simplified Disease Activity Index (SDAI) in an observational cohort of patients with rheumatoid arthritis. *Ann Rheum Dis* 2004;63:111.
9. Smolen JS. A comparison of the SDAI and DAS28 as measures of response in adalimumab (Humira™) clinical trials in rheumatoid arthritis (RA) [abstract]. *Arthritis Rheum* 2003;48 Suppl:S107.
10. Greenberg JD, Harrold LR, Bentley MJ, Kremer J, Reed G, Strand V. Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. *Rheumatology* 2009;48:686-90.
11. Smolen JS, Breedvald FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. *Rheumatology* 2003;42:244-57.
12. Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. *Arthritis Res Ther* 2005;7:R796-R806.
13. Felson D, American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. *Arthritis Rheum* 2007;57:193-202.
14. Wolfe F, Pincus T, Thompson AK, Doyle J. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. *Arthritis Rheum* 2003;49:59-63.
15. Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, Routine Assessment of Patient Index Data 3 (RAPID3), in two abatacept clinical trials: similar results to Disease Activity Score (DAS28) and other RAPID indices that include patient-reported measures. *Rheumatology* 2008;47:345-9.
16. Pincus T, Sokka T. Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. *Clin Exp Rheumatol* 2005;23:S1-9.
17. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studies over nine years. *Arthritis Rheum* 1984;27:864-72.
18. Sokka T, Häkkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the Health Assessment Questionnaire in patients

- with rheumatoid arthritis and the general population. *Ann Rheum Dis* 2004;63:494-7.
19. Boers M, Brooks P, Simon LS, Strand V, Tugwell P. OMERACT: An international initiative to improve outcome measurement in rheumatology. *Clin Exp Rheumatol* 2005;23 Suppl:S10-3.
  20. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology. *J Rheumatol* 1998;25:198-9.
  21. Kremer J. The CORRONA database. *Ann Rheum Dis* 2005;64 Suppl:iv37-41.
  22. Greenberg JD, Bingham CO 3rd, Abramson SB, Reed G, Sebaldt RJ, Kremer J. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. *Arthritis Rheum* 2005;53:12-7.
  23. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. *Arthritis Rheum* 1983;26:1346-53.
  24. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. *Clin Exp Rheumatol* 2005;23 Suppl:S100-S108.
  25. Ranganath VK, Yoon J, Khanna D, Park GS, Furst DE, Elashoff DA, et al. Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. *Ann Rheum Dis* 2007;66:1633-40.
  26. Miles J, Shevlin M. *Applying regression and correlation*. London: Sage Publications; 2001.
  27. Altman DG. *Practical statistics for medical research*. London: Chapman and Hall; 1991.
  28. Fleiss JL. *Statistical methods for rates and proportions*. 2nd ed. New York: John Wiley; 1981:38-46.
  29. Cohen J. *Statistical power analysis for the behavioural sciences*. 2nd ed. Rahway, NJ: Lawrence Erlbaum Associates; 1988.
  30. Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic evaluation. *Med Care* 1990;28:632-42.
  31. Beaton DE, Hogg-Johnson S, Bombardier C. Evaluating changes in health status: Reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders. *J Clin Epidemiol* 1997;50:79-93.
  32. Stata Corp. *Stata statistical software: Release 10.0*. College Station, TX: Stata Corp.; 2007.
  33. Smolen JS, Aletaha D. Activity assessments in rheumatoid arthritis. *Curr Opin Rheumatol* 2008;20:306-13.
  34. Leeb BF, Anel I, Sautner J, Bogdan M, Maktari A, Nothnagl T, et al. Disease activity measurement of rheumatoid arthritis: Comparison of the Simplified Disease Activity Index (SDAI) and the Disease Activity Score including 28 joints (DAS28) in daily routine. *Arthritis Rheum* 2005;53:56-60.
  35. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.
  36. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. *Br J Rheumatol* 1986;25:206-9.
  37. Sultan N, Pope JE, Clements PJ. The Health Assessment Questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: Results from an analysis of two randomized controlled trials in early diffuse scleroderma. *Rheumatology* 2004;43:472-8.
  38. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. *Arthritis Rheum* 2003;48:1530-42.
  39. Uhlig T, Haavardsholm EA, Kvien TK. Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis. *Rheumatology* 2006;45:454-8.
  40. Ziebland S, Fitzpatrick R, Jenkinson C, Mowat A, Mowat A. Comparison of two approaches to measuring change in health status in rheumatoid arthritis: The Health Assessment Questionnaire (HAQ) and modified HAQ. *Ann Rheum Dis* 1992;51:1202-5.
  41. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. *Leflunomide Rheumatoid Arthritis Investigators Group*. *Arch Intern Med* 1999;159:2542-50.
  42. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986;1:307-10.
  43. Osei-Bimpong A, Meek JH, Lewis SM. ESR or CRP? A comparison of their clinical utility. *Hematology* 2007;12:353-7.